Clinical trials: Huntington's Dementia
Huntington Disease
Mitochondrial Biomarkers in Huntington's Disease
The objective of this study is to discover a panel of mitochondrial metabolomics biomarkers for Huntington's disease.
- Trial name
- NCT04515550
- Testing
- lumbar puncture
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Huntington Disease
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
WVE-HDSNP1-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120101 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism…
- Trial name
- NCT04617847
- Testing
- WVE-120101
- Where
- 18 sites in Australia, Canada and 5 more
- Volunteers
- 27 people
- Sponsor
- Wave Life Sciences USA, Inc.
Huntington Disease
Development of the Virtual Unified Huntington's Disease Rating Scale
The Huntington Study Group currently holds the registered trademark for the Unified Huntington's Disease Rating Scale. The UHDRS® is a research tool which has been developed by the HSG to provide a uniform assessment of the…
- Trial name
- vUHDRS (NCT05748288)
- Where
- 17 sites in United States
- Volunteers
- 60 people
- Sponsor
- Huntington Study Group
Huntington Disease
Beta Testing of a New Assessment in Huntington's Disease (HD)
Huntington's disease (HD) is an inherited neurodegenerative disease for which there are no existing disease-modifying treatments.
- Trial name
- CAPIT-HD Beta (NCT03119246)
- Testing
- CAPIT-HD beta
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Huntington Disease
FuRST 2.0 Cognitive Pre-testing - Round 2
The study is a single, cross-sectional cognitive interview of FuRST 2.0, functional rating scale, administered to forty Huntington's Disease Gene Expansion Carriers (HDGECs) and potentially, their companions (the companion's…
- Trial name
- NCT03709173
- Testing
- FuRST 2.0
- Where
- 4 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- CHDI Foundation, Inc.
Huntington Disease
Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD)
Huntington's disease (HD) is a neurodegenerative pathology characterized by choreic hyperkinesias which represent the typical motor symptom and are represented by involuntary, aimless, irregular, recurrent, unpredictable and…
- Trial name
- NCT06976983
- Testing
- Portable ergonomic helmet for real tSMS
- Volunteers
- 30 people
- Sponsor
- Neuromed IRCCS
Huntington Disease
Handgrip and Respiratory Dysfunction in HD Patients.
Hereditary neurodegenerative diagnosis of Huntington's disease (HD) is associated with a progressive deterioration of the respiratory system function .
- Trial name
- NCT06585332
- Testing
- Assessment of respiratory paramenters (Maximal inspiratory pressure, maximal expiratory pressure, and voluntary peak cough flow))
- Where
- Czechia
- Volunteers
- 70 people
- Sponsor
- General University Hospital, Prague
Huntington's Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease
This study tested the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ISIS 443139 administered intrathecally to adult participants with early manifest Huntington's Disease.
- Trial name
- NCT02519036
- Testing
- ISIS 443139 10 mg, ISIS 443139 30 mg, ISIS 443139 60 mg
- Where
- 9 sites in Canada, Germany and 1 more
- Volunteers
- 46 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Huntington's Disease
Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)
To establish the tolerability of treatment with 600, 1200 or 2400 mg per day of coenzyme Q10 in pre-manifest participants carrying the CAGn expansion for Huntington's Disease (HD).
- Trial name
- PREQUEL (NCT00920699)
- Testing
- CoQ10
- Where
- 13 sites in United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
Early Manifest Huntington Disease
A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be…
- Trial name
- VIBRANT-HD (NCT05111249)
- Testing
- Branaplam
- Where
- 12 sites in Canada, France and 3 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Huntington Disease
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers
To assess the safety and tolerability of five doses of PBF-999 (160 mg and 320mg) after repeated (8 days) single daily oral dose administration in young male and female healthy subjects.
- Trial name
- NCT02907294
- Testing
- PBF-999 / 160 mg, PBF-999 / 320 mg
- Where
- Spain
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL
Alzheimer's Disease, Amyotrophic Lateral Sclerosis
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
This is a prospective investigation of the effects of Laughter therapy (LT) on perceived stress, self-efficacy, mood and other wellness measures in people with the following neurological conditions: Alzheimer's disease…
- Conditions
- Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease
- Trial name
- NCT02750982
- Testing
- Laughter Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Huntington Disease
A Pre-Cellular Therapy Observational Study in Early Huntington's Disease
This observational study will establish a clinical baseline and measure changes over time in movement, thinking, behavior, brain imaging, blood and spinal fluid markers in subjects with early stage Huntington's disease.
- Trial name
- PRE-CELL (NCT01937923)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of California, Davis
Huntington's Disease
PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease
Deep Brain Stimulation (DBS) of the Globus pallidus internus(GPi) is useful in the treatment of different forms of chorea, including Huntington's disease (HD).
- Trial name
- NCT02263430
- Testing
- Deep Brain Stimulation
- Volunteers
- 8 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Huntington Disease
Characterization and Quantification of Motor Speech Disorders in Huntington's Disease: Identification of Acoustic Markers
The study proposes to identify deviant speech dimensions in patients with HD at presymptomatic and declared stages of the disease, compared to healthy subjects, using the computerized MonPaGe speech protocol.
- Trial name
- TPMH (NCT04630574)
- Testing
- Speech evaluation with the clinical evaluation of dysarthria, complete assessment of the MonPaGe computerized protocol
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Bordeaux
Brain Damage, Chronic
The Effect of tDCS on Subcortical Brain Functioning
This research is being done to determine whether transcranial direct current stimulation (tDCS) can improve certain abilities related to cognition, emotion and/or physical functioning in individuals with subcortical brain damage.
- Trial name
- NCT01602276
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Huntington Disease
Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HD
Huntington's disease is a rare and fatal monogenic neurodegenerative disorder whose molecular origin is an expansion of CAG triplets within the first exon of the Huntingtin gene.
- Trial name
- FibroTG-HD (NCT06444217)
- Testing
- skin biopsy
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Angers
Huntington's Disease
Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers
The aim of this study is to measure longitudinally the availability of the PDE10A enzyme in HDGECs using the radioligand [18F]MNI-659.
- Trial name
- LONGPDE10 (NCT02956148)
- Testing
- Radioligand [18F]MNI-659
- Where
- 7 sites in Denmark, Netherlands and 2 more
- Volunteers
- 45 people
- Sponsor
- CHDI Foundation, Inc.
Huntington's Disease
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).
- Trial name
- Open PRIDE-HD (NCT02494778)
- Testing
- Pridopidine
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 248 people
- Sponsor
- Prilenia
Huntington Disease
Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)
Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.
- Trial name
- NCT00675077
- Testing
- Far Infrared Radiation
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- GAAD Medical Research Institute Inc.